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ABSTRACT 
The influence of the particle size of colloidal dispersion on nasal absorption and the localization of Ondansetron hydrochloride in the dispersion 
have been investigated in rats. Using scanning electron microscopy, it was found that the freeze-drying process, which was used to load 
Ondansetron hydrochloride into the colloidal dispersions, had a significant impact on the integrity and surface properties of  the nasal epithelium in 
rats. The optimized formulation was analyzed for the sterility by (total bacterial count) and stability study, which proved that the formulation does 
not contain bacteria and fungi, found to be stable up to 3 years. Pharmacokinetics study was carried out in Wistar rats for Cmax, tmax and AUC, which 
was found to be 2 h, 0.5 h and 0-2 h respectively. It has been concluded that the tendency of the particle size influence the kinetics of the 
Ondansetron effect curve. 
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INTRODUCTION   
Systemic delivery of drugs via the nasal route as an alternative, has 
many advantages, it is usually limited by the specific nasal 
morphological and physiological characteristics [1]. One of the most 
important disadvantages is a nasal mucociliary clearance that limits 
the time allowed for drug absorption to occur. Thus, the mucous 
adhesive colloidal dispersion has been developed in order to 
decrease the effect of mucociliary clearance [2]. Colloidal 
dispersions also exert a direct effect on the mucosa resulting in the 
opening of tight junctions between the epithelial cells. Colloidal 
dispersions are an alternative process that is cheaper and faster than 
all other techniques to prepare nasal particles from mucoadhesive 
polymers. 
β-cyclodextrin derivatives are  biodegradable, biocompatible, 
bioadhesives  properties of colloidal dispersion due to its 
hydrophilic. It is a polymer of choice, because it enhances the nasal 
absorption of low molecular weight molecules. Ondansetron is a 
serotonin (5-hydroxytryptimine) subtype 3 (5-HT) receptor 
antagonists used in the management of nausea and vomiting [3]. 
Oral administration of Ondansetron hydrochloride is well with 
bioavailability of 60% with half life of 3.1h [4]. The aim of this work 
is to evaluate the optimized formulation [5] which was developed 
with trails of Ondansetron hydrochloride for nasal absorption and 
the localization of the drug in the dispersions has been investigated 
in rats [6]. 
MATERIALS AND METHODS 
Ondansetron hydrochloride USP was obtained as a gift sample from 
Secure healthcare Chennai, Pvt. Ltd. β-cyclodextrin and hydroxyl 
propyl β-cyclodextrin were purchased from Signet chemicals, 
Mumbai.  All animal experiments adhered to the principles for 
biomedical research involving animals developed by council for 
international organizations of medical sciences. Wistar rats weighing 
180-200g were received from the central animal house (CAH), 
Annamalai University after getting approval from the institutional 
animal ethical committee (IAEC no. 160/1999/CPCSEA/829). All 
surgical procedure was performed under anesthesia with ether and 
an intraperitoneal injection of 0.2ml/kg Xylocaine. 
Characterization of colloidal dispersions 
Morphological studies of colloidal dispersions 
The structural feature of forming a colloidal dispersion after  
 
 
lyophilization was observed by SEM6700F scanning electron 
microscopy   (SEM, JEOC, Japan).   The   sample was fixed on a metal 
stub with conductive carbon type and was coated with gold under 
vacuum by an ion sputter (JFC-1600, JEOL, Japan). 
Particle size 
It is important that the size of the colloidal dispersion for nasal 
delivery should above 10µ, if the particle size is less than 10µ, this 
size would able to be carried by the air stream down into the trachea 
bronchial region [7]. Larger particles will remain deposited in the 
anterior insulated portion of the nose and thus a size range of 40-
60µ was chosen for colloidal dispersion, which is observed by the 
particle size analyzer (Malvaniser Particle size analyzer, UK). The 
particle size was expressed as mean volume diameter. 
Total microbial count  
It was carried out by using the filter paper disc diffusion method [7], 
employing 24h culture of the Salmonella Sp (ATCC 35664), 
Escherichia coli (ATCC 35218), Staphylococcus Sp (ATCC 43957) and 
Pseudomonas Sp (ATCC 15915). The test organisms were seeded in 
sterile nutrient agar mediums by uniformly mixing one ml of 
inoculum with 20 ml sterile melted nutrient agar cooled to 48-50ºC 
in a sterile petridish. The medium was allowed to solidify. The 
optimized formulation with a concentration of 5%v/v was prepared 
in a sterile dimethyl formamide (DMF) as solvent. The optimized 
formulation and Ciprofloxacin (100µg/ml) standard drug as well as 
blank was impregnated in Whatman filter paper disc and placed on 
solidified medium in the petridish and the petridish was left 
undisturbed for two hours at room temperature. The petridish was 
then incubated at 37ºC for 24h and zone of inhibition was measured.  
Sterile yeast nitrogen base (Himedia) with 2% agar was inoculated 
with Aspergillus niger(ATCC 1015), Microsperum gypserm (ATCC 
24102), Candida albicans (ATCC 10231) by rotating swab (soaked in 
standard inoculum suspension) over the surface of the media. The 
solvent DMF was used as a control. The optimized formulation and 
Flucanazole (100mµg/ml) standard drug as well as blank was 
impregnated in Whatman filter paper disc and placed on solidified 
medium in the petridish and the petridish was left undisturbed for 
two hours at room temperature. The petridish was then incubated at 
37ºC for 24h and zone of inhibition was measured. All the 
operations were carried out in a laminar air flow chamber. The 
results were recorded as colony forming units per gram of material.  
 
 Vol 7, Issue 1, 2014                                                                                                                                                                                                        ISSN - 0974-2441                                                                                                                                                                                                 
Menaka et al. 
Asian J Pharm Clin Res, Vol 7, Issue 1, 2014, 72-75 
73 
 
Pharmacokinetic studies  
Rats were divided into three groups of six animals each for nasal, 
intravenous and oral. Each group comprised of six samples for each 
time point. Blood samples were withdrawn from the orbital plexus 
of rat and collected in an EDTA coated vacuette tube and centrifuged 
at 3000 RPM for about 10 minutes to separate the serum for 
analysis. The brain was removed immediately and weighed. One 
gram of the brain sample was stored in 10% formalin solution at -
700C until analyzed. 
For intravenous administration of Ondansetron hydrochloride 8 mg 
was dissolved in 9 ml of normal saline, filtered through 0.2µ 
membrane filter, and injected through the jugular vein which was 
cannulated using polyethylene tube (0.76 mm i d × 1.22m od). Prior 
to oral administration, the animals were fasted overnight and kept 
under fasted conditions until 4h, after oral administration of a single 
dose of 4mg/ml Ondansetron hydrochloride. Blood samples were 
collected at 10, 15, 20, 25, 30, 45, 60 minutes and used for further 
studies. 
The nasal absorption study of Ondansetron hydrochloride was 
conducted using an in vivo experimental technique [9]. A single dose 
of the constant volume of 2ml/kg was administered into one nostril 
using a micro syringe. Blood samples were collected at 
predetermined time intervals 10, 15, 20, 25, 30, 45, 60 minutes and 
used for further studies.  
Pharmacokinetic parameters 
The first order terminal elimination rate constant (ke) was 
estimated by linear regression from the points describing the 
elimination phase on a log linear plot. Half life (t1/2) was derived 
from the rate constant (t1/2= in (2)/ke). The maximum observed 
plasma concentration (Cmax) and time taken to achieve this 
concentration (Tmax) were obtained directly from curves. The AUC 
(0-2h) was calculated using the trapezoidal formula. 
The pharmacokinetic variables from three dosage forms were 
compared with a one way ANOVA, which followed by a posterior 
testing with an unpaired t-test using the Bonferroni correction. A ‘P’ 
value of less than 0.05 was considered significant.    
Estimation of Ondansetron hydrochloride 
Plasma sample 5 ml was mixed with 100 µl of working IS [internal 
standard] solution and alkalized with 20 µl of 2M sodium hydroxide 
solution. The mixer was added to 50 ml of acetonitrile, vortexed for 
10min, and centrifuged for 15 min. 5ml of organic phase was back 
extracted into 100 µl  of 0.05% phosphoric acid by vortex mixing for 
3 min and  then 20 µl of the aqueous phase  was injected directly 
into the above HPLC system.   
Evaluation of nasal tissue morphology and mucociliary 
clearance 
Several absorption enhancers were investigated in animal tissue for 
histological effects. PEG, PVP, MCC, β-cyclodextrin, hydroxyl propyl 
β-cyclodextrin has been investigated in animal tissue for the 
histological effects using 5-10min contact time with the nasal 
epithelium. The toxicity of nasal absorption enhancer has been 
estimated in recent years by measuring their effect on the 
mucociliary transport rate nasal morphology and ciliary beat 
frequency [10]. The potential toxicity of some absorption enhancer 
has been tested with the wistar rat model [11]. Measuring the effect 
of absorption enhancer by mucociliary transport rate, before and 
after application of the formulation.  
Stability studies 
Stability studies were conducted for the optimized formulation, 
which was subjected to the following long term stability studies at 
300C±20C/65%RH±5%RH and accelerated stability studies at 
400C±20C/75%RH±5%RH and analyzed for drug content, pH 
viscosity, clarity, crystallization, weight loss, (formulation stored 
under upward , inverted, horizontal, position leakage, water loss) 
and particle size. From the results obtained from accelerated 
stability studies the shelf life of the product was determined. The 
optimized formulation was placed at different temperature 
conditions as per ICH guidelines. Samples were withdrawn at 
regular intervals and the percentage of drug content was 
determined. Shelf life was estimated with upper and lower 
acceptance criteria based on assay at 400C±20C/75%RH±5%RH. 
Drug content was estimated by HPLC method, (Shimadzu, Japan) 
was estimated at regular intervals of time. The samples were 
checked for clarity for crystal growth, pH changes using a digital pH 
meter and viscosity by Viscometer (DV model). 
RESULTS AND DISCUSSION 
Morphological studies of colloidal dispersions 
Examination of the structural feature of forming a colloidal 
dispersion after lyophilization was observed by scanning electron 
microscope. It reveals that the changes in the structure of the 
colloidal dispersion, which was analyzed before and after the 
stability studies. The structure of the colloidal dispersions was 
smooth surface and no obvious pores were observed on the surface 
which could be shown in Figure 1. The smooth surface was altered 
and a significant number of large holes could be seen on the surface 
spherical form dramatically changed after stability studies shown in 
Figure 2. 
 
Figure 1: SEM photomicrograph of colloidal dispersion prior to 
stability study 
 
Figure 2: SEM photomicrograph of colloidal dispersion after the 
stability study 
Particle size 
Examination of the colloidal particles in particle size analyzer and it 
showed an increase in particle size after freeze drying, whereas 
larger size was not influenced (Table 1 and 2).  The two different 
qualities of the colloidal dispersions, before and after the stability 
study revealed the significant difference between size and structure. 
Particle size and morphology are also important to minimize the feel 
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of grittiness and possibly irritating to nasal cavity. Too fine particles, 
below five microns may be inhaled into lungs and deposited in the 
nostrils so that to be avoided for nasal products. 
Total microbial count 
The results were recorded as colony forming units per gram of 
material. It was observed that, both the bacteria and fungi colony 
forming unit was found to be less than 5cfu/ml. Hence it is inferred 
that the formulation does not contain any microorganism. 
Benzalkonium chloride 0.02%, sodium chloride 0.09% plays vital 
roles in as antimicrobial agent. 
In vivo pharmacokinetics results 
Based on the in vitro results from stability of Ondansetron 
hydrochloride nasal delivery systems, aqueous solution containing 
PEG, PVP, β-cyclodextrin, hydroxyl propyl β-cyclodextrin, was 
employed as biocompatible polymers for the in vivo 
pharmacokinetic study of Ondansetron hydrochloride nasal delivery 
system. 
 As shown in Table 1 Ondansetron hydrochloride was rapidly 
absorbed through nasal route. The mean C max of Ondansetron by 
nasal route was found to be 2 times higher than that by oral route, 
which was statistically significant (P<0.5). The AUC (0-2h) after 
nasal administration was significantly higher than that after oral 
administration (P 0.01) and comparable to intravenous 
administration. The time to reach (Cmax) after nasal administration 
was found faster than that by oral administration, even though, the 
difference was significant.      
Table1: Pharmacokinetic parameters of Ondansetron 
hydrochloride after intravenous, intranasal and oral 
administration in rats. 
Parameter Nasal Oral I.V 
N 5 5 5 
C max(ng/ml) 49.2±20.5 28.6±10.1 -- 
T max 8.5±1.92 10.6±1.82 -- 
AUC 0-2h 53.9±8.2 22.5±10.6 49.04±7.8 
Data were expressed as the mean ±SD. Statistically significant 
difference formed administration.(p*<0.05,**p<0.01)  
Effects on nasal tissue morphology and mucociliary clearance 
Immediately after the application of the formulation, no effect was 
observed on the mucociliary transport route. All these enhancers 
were reported more or less severe epithelium disruption. The effect 
of several enhancers was studied on the surface morphology of rat 
nasal mucosa. The optical microscope is used to characterize the 
gross structural and cellular changes. After the exposure of 5-10 min 
to the enhancer, micrographs of the nasal tissue were evaluated 
mainly for surface integrity, ciliary morphology, mucus, extracellular 
debris.   
For each absorption enhancers investigated, the duration of 
exposure did not result in large differences in score numbers [score 
0: No erythema, score 1: Very slight erythema, score 2: Well defined 
erythema, score 3: Moderate to severe erythema and score 4: Severe 
erythema (beet redness)]. 
 The observation was performed at 30 min, 1 h, 3 h, 12 h & 24 h and 
the erythema was determined. From the data mucosa irritation 
index was calculated. As evident of Table 4, the order of increasing 
morphological damage caused by enhancer was PEG (2%) <<PVP 
(2%) << MCC (2%) << β-cyclodextrin (4%) << hydroxyl propyl β-
cyclodextrin (5%), which was discussed in Table 2. PEG showed the 
lowest scoring, almost similar to the control phosphate buffer, but 
exposure to PVP, MCC, β-cyclodextrin and hydroxyl propyl β-
cyclodextrin resulted in severe erosion of the nasal mucosa within 5-
10 min (mean scores 4.6 to 5) indicating total loss of cells and ciliary 
identity as well as prevalence of extracellular debris. Even though β-
cyclodextrin moderate irrational, it is temporally for 5-10 min and 
this polymer maintain pH, viscosity, stability of the formulation. 
 
Table 2:  In vivo effects of absorption enhancer on surface 
morphology of rat nasal mucosa 
Absorption enhancer   Exposure 
time (min) 
Mean scores of mucous 
irritation index (cat-I-III) 














Mean score of categories I (mucosal surface integrity), II (ciliary 
morphology) and III (mucus /extra cellular debris); optical 
microscopy of rat nasal mucosa were scored from 0 (No erythema), 
1 (Very slight erythema ), 2 (Well defined erythema), 3 (Moderate to 
severe erythema), 4 (Severe erythema (beet redness). 
Stability studies 
From the study it was revealed that the drug content was found to 
be 95.9% and 100.26% receptively, the pH of the formulation was 
found to be 5.4, the viscosity of the formulation was found to be 
4.4cps, there was no crystal growth and weight loss (formulation 
stored under upward, inverted, horizontal position no leakage, 
water loss), which indicates that the formulation is stable in long 
and short term stability studies, since all the results are within the 
limit. The marginal particle size increases in average, possibly due to 
clumping of colloidal dispersions. This is probably due to stress, 
increasing temperature which precipitates the formulation shown in 
Figure 2. 
 Colloidal dispersion was placed at different temperature conditions 
and the samples were withdrawn at regular interval of  time and the 
percentage of drug  remaining was determined. The shelf life was 
estimated  with upper and lower acceptance criteria based on assay 
at 40ºC±2ºC & 75%RH±5%RH.  From the data it was found to be 
that the developed optimized formulation was stable up to 3.2 years.    
The optimized formulation was found to be more stable, when it is 
subjected to the short term and long term stability study.      
Table 3: Long term stability study for optimized formulation 
Months Drug 
content% 
Clarity Viscosity pH Average 
size (µm) 
0 102.9±1.1 - 4.42 5.61 8.9 
3 100.4±0.5 - 4.43 5.55 9.9 
6 99.5±2.6 - 4.40 5.44 10.0 
9 99.2±0.6 - 4.43 5.25 10.2 
12 99.1±1.1 - 4.3 5.21 10.1 
 100.26 - 4.4 5.4 9.82 
n=3; - no turbid forms. 
Table 4: Accelerated stability study for optimized formulation 
Months Drug 
content% 
clarity Viscosity pH Average 
size (µm) 
0 102.7±0.1 - 4.42 5.61 8.9 
2 99.73±1.2 - 4.43 5.55 10.6 
4 94.42±1.9 - 4.40 5.44 11.3 
6 87.01±4.0 - 4.33 5.25 10.6 
 95.9  4.4 5.4 10.35 
n=3; - no turbid forms. 
CONCLUSION 
In conclusion as a novel nasal drug delivery system the colloidal 
dispersion should meet several requirements, especially low cyto 
and systemic toxicity.  PEG, PVP, β-cyclodextrin, hydroxyl propyl β-
cyclodextrin, used in this formulation is non toxic and biocompatible 
polymers. β-cyclodextrin even at high concentration not relevant, 
because     the   residence  time in  the nose is very limited. Optimized  
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formulation of Ondansetron hydrochloride nasal delivery system 
was sterile, posses better pharmacokinetics activity, stable for 3 
years. It is feasible for nasal administration at low concentration of 
the drug and rapidly its antiemetic effect.    
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